BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20117845)

  • 1. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein.
    Kuhle J; Regeniter A; Leppert D; Mehling M; Kappos L; Lindberg RL; Petzold A
    J Neuroimmunol; 2010 Mar; 220(1-2):114-9. PubMed ID: 20117845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of CSF neurofilament light and heavy chain protein in MS.
    Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
    Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axonal damage markers in cerebrospinal fluid are increased in ALS.
    Brettschneider J; Petzold A; Süssmuth SD; Ludolph AC; Tumani H
    Neurology; 2006 Mar; 66(6):852-6. PubMed ID: 16567701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases.
    Gaiottino J; Norgren N; Dobson R; Topping J; Nissim A; Malaspina A; Bestwick JP; Monsch AU; Regeniter A; Lindberg RL; Kappos L; Leppert D; Petzold A; Giovannoni G; Kuhle J
    PLoS One; 2013; 8(9):e75091. PubMed ID: 24073237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
    Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
    Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.
    Oe T; Ackermann BL; Inoue K; Berna MJ; Garner CO; Gelfanova V; Dean RA; Siemers ER; Holtzman DM; Farlow MR; Blair IA
    Rapid Commun Mass Spectrom; 2006; 20(24):3723-35. PubMed ID: 17117458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilament heavy chain and heat shock protein 70 as markers of seizure-related brain injury.
    Rejdak K; Kuhle J; Rüegg S; Lindberg RL; Petzold A; Sulejczak D; Papuc E; Rejdak R; Stelmasiak Z; Grieb P
    Epilepsia; 2012 May; 53(5):922-7. PubMed ID: 22509781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.
    Kuhle J; Barro C; Andreasson U; Derfuss T; Lindberg R; Sandelius Å; Liman V; Norgren N; Blennow K; Zetterberg H
    Clin Chem Lab Med; 2016 Oct; 54(10):1655-61. PubMed ID: 27071153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA.
    Koel-Simmelink MJ; Vennegoor A; Killestein J; Blankenstein MA; Norgren N; Korth C; Teunissen CE
    J Immunol Methods; 2014 Jan; 402(1-2):43-9. PubMed ID: 24275679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes.
    Brettschneider J; Petzold A; Süssmuth SD; Landwehrmeyer GB; Ludolph AC; Kassubek J; Tumani H
    Mov Disord; 2006 Dec; 21(12):2224-7. PubMed ID: 17013909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis.
    Kuhle J; Leppert D; Petzold A; Regeniter A; Schindler C; Mehling M; Anthony DC; Kappos L; Lindberg RL
    Neurology; 2011 Apr; 76(14):1206-13. PubMed ID: 21346223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
    Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
    Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilament heavy subunit in cerebrospinal fluid: a biomarker of amyotrophic lateral sclerosis?
    Mendonça DM; Martins SC; Higashi R; Muscara MN; Neto VM; Chimelli L; Martinez AM
    Amyotroph Lateral Scler; 2011 Mar; 12(2):144-7. PubMed ID: 21198418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.
    Petzold A; Eikelenboom MJ; Keir G; Grant D; Lazeron RH; Polman CH; Uitdehaag BM; Thompson EJ; Giovannoni G
    J Neurol Neurosurg Psychiatry; 2005 Feb; 76(2):206-11. PubMed ID: 15654034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain.
    Petzold A; Shaw G
    J Immunol Methods; 2007 Jan; 319(1-2):34-40. PubMed ID: 17140597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases.
    Brettschneider J; Widl K; Ehrenreich H; Riepe M; Tumani H
    Neurosci Lett; 2006 Sep; 404(3):347-51. PubMed ID: 16815630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament Light Chain Determination from Peripheral Blood Samples.
    Limberg M; Disanto G; Barro C; Kuhle J
    Methods Mol Biol; 2016; 1304():93-8. PubMed ID: 25687302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF neurofilament levels: a potential prognostic marker in Guillain-Barré syndrome.
    Petzold A; Hinds N; Murray NM; Hirsch NP; Grant D; Keir G; Thompson EJ; Reilly MM
    Neurology; 2006 Sep; 67(6):1071-3. PubMed ID: 17000982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofilament ELISA validation.
    Petzold A; Altintas A; Andreoni L; Bartos A; Berthele A; Blankenstein MA; Buee L; Castellazzi M; Cepok S; Comabella M; Constantinescu CS; Deisenhammer F; Deniz G; Erten G; Espiño M; Fainardi E; Franciotta D; Freedman MS; Giedraitis V; Gilhus NE; Giovannoni G; Glabinski A; Grieb P; Hartung HP; Hemmer B; Herukka SK; Hintzen R; Ingelsson M; Jackson S; Jacobsen S; Jafari N; Jalosinski M; Jarius S; Kapaki E; Kieseier BC; Koel-Simmelink MJ; Kornhuber J; Kuhle J; Kurzepa J; Lalive PH; Lannfelt L; Lehmensiek V; Lewczuk P; Livrea P; Marnetto F; Martino D; Menge T; Norgren N; Papuć E; Paraskevas GP; Pirttilä T; Rajda C; Rejdak K; Ricny J; Ripova D; Rosengren L; Ruggieri M; Schraen S; Shaw G; Sindic C; Siva A; Stigbrand T; Stonebridge I; Topcular B; Trojano M; Tumani H; Twaalfhoven HA; Vécsei L; Van Pesch V; Vanderstichele H; Vedeler C; Verbeek MM; Villar LM; Weissert R; Wildemann B; Yang C; Yao K; Teunissen CE
    J Immunol Methods; 2010 Jan; 352(1-2):23-31. PubMed ID: 19857497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
    Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.